ATE308548T1 - Glycerophosphoinositol-derivate als cytosolic a2 phospholipase modulatoren - Google Patents

Glycerophosphoinositol-derivate als cytosolic a2 phospholipase modulatoren

Info

Publication number
ATE308548T1
ATE308548T1 AT00981612T AT00981612T ATE308548T1 AT E308548 T1 ATE308548 T1 AT E308548T1 AT 00981612 T AT00981612 T AT 00981612T AT 00981612 T AT00981612 T AT 00981612T AT E308548 T1 ATE308548 T1 AT E308548T1
Authority
AT
Austria
Prior art keywords
modulators
derivatives
glycerophosphoinositol
cytosolic
phospholipase
Prior art date
Application number
AT00981612T
Other languages
English (en)
Inventor
D Corda
Original Assignee
I R B Istituto Di Ricerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by I R B Istituto Di Ricerche Bio filed Critical I R B Istituto Di Ricerche Bio
Application granted granted Critical
Publication of ATE308548T1 publication Critical patent/ATE308548T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C07F9/106—Adducts, complexes, salts of phosphatides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C07F9/177—Esters of thiophosphoric acids with cycloaliphatic alcohols

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
AT00981612T 2000-11-07 2000-11-07 Glycerophosphoinositol-derivate als cytosolic a2 phospholipase modulatoren ATE308548T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2000/000447 WO2002038575A1 (en) 2000-11-07 2000-11-07 Glycerophosphoinositol derivatives as modulators of cytosolic a2 phospholipase

Publications (1)

Publication Number Publication Date
ATE308548T1 true ATE308548T1 (de) 2005-11-15

Family

ID=11133577

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00981612T ATE308548T1 (de) 2000-11-07 2000-11-07 Glycerophosphoinositol-derivate als cytosolic a2 phospholipase modulatoren

Country Status (11)

Country Link
US (1) US7625883B1 (de)
EP (1) EP1332149B1 (de)
JP (1) JP2004513176A (de)
CN (1) CN1300155C (de)
AT (1) ATE308548T1 (de)
AU (1) AU2001218841A1 (de)
CA (1) CA2427352C (de)
DE (1) DE60023758T2 (de)
ES (1) ES2252079T3 (de)
IL (2) IL155619A0 (de)
WO (1) WO2002038575A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
EP1773352B1 (de) * 2004-07-09 2013-10-09 Vascular Biogenics Ltd. Verbessertes verfahren zur herstellung von oxidierten phospholipiden
GB0510463D0 (en) * 2005-05-23 2005-06-29 Britania Pharmaceuticals Ltd Improvements in or relating to organic materials
AU2006344178A1 (en) * 2006-06-09 2007-12-13 Erasmus University Medical Center Rotterdam Modulation of the immune system by inositol phospholipids
JP2010516731A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物
EP2187892A1 (de) * 2007-09-17 2010-05-26 Bioneris AB Verfahren und mittel zur behandlung von kachexien
JP5420848B2 (ja) * 2008-02-28 2014-02-19 株式会社コーセー 美白剤及び美白用皮膚外用剤
JP2009269851A (ja) * 2008-05-07 2009-11-19 Nikko Chemical Co Ltd プロスタグランジンｅ２産生抑制剤及びその利用
WO2012158591A1 (en) * 2011-05-18 2012-11-22 The Research Foundation Of State University Of New York Anti-blepharitis products and methods
JP5670858B2 (ja) * 2011-10-14 2015-02-18 イ．エルレ．ビ．イスティトゥト ディ リチェルケ ビオテクノロジケ ソチエタ ペル アツィオニ サイトゾルのホスホリパーゼのモジュレーターとしてのグリセロホスホイノシトール誘導体
ITRM20120473A1 (it) 2012-10-04 2014-04-05 Consiglio Nazionale Ricerche Use of glycerophosphoinositols for the treatment of septic shock
JP5701371B2 (ja) * 2012-12-28 2015-04-15 花王株式会社 スフィンゴミエリン含有サプリメント
RU2580280C2 (ru) * 2014-07-08 2016-04-10 Общество с ограниченной ответственностью "НИТРОЗДРАВ" Композиция для местного применения для снижения или снятия болевого синдрома
US20170304409A1 (en) * 2014-09-24 2017-10-26 ISTITUTO PROFILATTICO E FARMACEUTICO CANDIOLI & C. SPA in abbreviated form CANDIOLI FARMACEUTICI Compositions useful for the prevention and/or treatment of infections and inflammations
CN104447856A (zh) * 2014-12-11 2015-03-25 河南省农科院农副产品加工研究所 一种甘油磷脂酰肌醇的制备方法
IT202200010199A1 (it) * 2022-05-17 2023-11-17 Plantarei Biotech S R L Glicerofosfoinositolo nella prevenzione e nel trattamento di infezioni da covid-19 e metodo per il suo ottenimento

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2659048A1 (de) * 1976-12-27 1978-07-06 Nattermann A & Cie Neue inositphosphatid-derivate und verfahren zur herstellung dieser verbindungen
FR2517310A1 (fr) * 1981-11-27 1983-06-03 Unilever Nv Derives d'a-glycerophosphatidester, procede pour leur preparation, composition cosmetique ou pharmaceutique les contenant
US4585762A (en) * 1982-07-30 1986-04-29 Fujisawa Pharmaceutical Co., Ltd. Phospholipid derivatives, processes for use thereof and pharmaceutical composition of the same
US4997761A (en) * 1987-10-06 1991-03-05 Houston Biotechnology Incorporated Phosphatidyl treatment of viral disease
IT1239474B (it) * 1989-10-27 1993-11-02 Depha Team Srl Composizioni farmaceutiche a base di l-alfa-glicerofosforil-d-myo- inositolo o suoi sali alcalini o alcalino-terrosi per la terapia delleneuropatie periferiche di origine dismetabolica o tossica, e delle cerebropatie su base organica e funzionale
IT1238683B (it) * 1990-02-09 1993-09-01 Istituto Chemioterapico Procedimento di preparazione di l-a-glicerilfosforil-d-myoinositolo e suoi sali da fosfatidi grezzi o parzialmente purificati
IT1247093B (it) * 1991-01-22 1994-12-12 Flarer S R L Ora Castellini S Derivati salini del gliceril fosforil mioinositolo ad attivita' terapeutica, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
US5464754A (en) * 1993-08-17 1995-11-07 The Regents Of The University Of California Assay and substrate for arachidonoyl-specific phospholipase A2
US5478857A (en) * 1993-12-23 1995-12-26 Eli Lilly And Company Use of PLA2 inhibitors as treatment for alzheimer's disease
DE19623950A1 (de) * 1996-06-15 1997-12-18 Boehringer Ingelheim Kg Pharmazeutische Zubereitung in Form von Liposomen
US6801860B1 (en) * 1999-02-15 2004-10-05 Genetics Institute, Llc Crystal structure of cPLA2 and methods of identifying agonists and antagonists using same
SE532388C2 (sv) * 2008-03-14 2010-01-12 Tetra Laval Holdings & Finance Förpackningslaminat och -behållare med två separata gasbarriärskikt samt metod för deras framställning

Also Published As

Publication number Publication date
IL155619A0 (en) 2003-11-23
EP1332149B1 (de) 2005-11-02
US7625883B1 (en) 2009-12-01
IL155619A (en) 2010-06-30
CN1455779A (zh) 2003-11-12
WO2002038575A1 (en) 2002-05-16
CN1300155C (zh) 2007-02-14
CA2427352C (en) 2010-10-12
DE60023758T2 (de) 2006-12-07
EP1332149A1 (de) 2003-08-06
JP2004513176A (ja) 2004-04-30
AU2001218841A1 (en) 2002-05-21
CA2427352A1 (en) 2002-05-16
DE60023758D1 (en) 2005-12-08
ES2252079T3 (es) 2006-05-16

Similar Documents

Publication Publication Date Title
DE60023758D1 (en) Glycerophosphoinositol-derivate als cytosolic a2 phospholipase modulatoren
DE69925133D1 (de) Pyrrolobenzodiazepine
BR9902086A (pt) Formulações farmacêuticas.
NL350077I2 (nl) Cyprosulfamide
HN1998000036A (es) Compuesto de pirazina
DOP2001000151A (es) Derivados de imidazopirimidina y derivados de triazolopimidina.
AR038434A2 (es) Compuesto 14,15-dihidro-16-oxoparahercuamida y compuestos 2-desoxo de parahercuamida y marcfortina
CY1108522T1 (el) Μεθοδος συνθεσης της περινδοπριλης και των φαρμακευτικως αποδεκτων αλατων της
BR9909819A (pt) Amida, uso de amidas, e, preparação farmacêutica para uso oral, parenteral ou intraperitoneal
BR0212386A (pt) Composto, formulação farmacêutica, e, uso de um composto
DE60041761D1 (de) Tribonektine
BR0314058A (pt) Composições para cuidados pessoais a base de álcool ramificado
BR9813817A (pt) Análogos de hemiasterlina
BR0114379A (pt) Derivados de c-ciclohexilmetilamina substituìdos
DE69712888D1 (de) ZUSAMMENSTELLUNGEN DIE beta-AMYLOID PROTEIN BEDINGTE ZYTOTOXIZITÄT VERHINDERN
BR9915692A (pt) Monohidrato de bromidrato de eletriptano
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
BR9812085A (pt) "método para a sìntese de derivados de quinolina"
DE69936052D1 (de) N1 modifizierte glycopeptide
ATE305517T1 (de) Neurotrypsin
UY26574A1 (es) " procedimiento para la separación enzimática de racematos de derivados de aminometil-aril-ciclohexanol".
BR0016941A (pt) Derivados de aminometil-fenil-ciclohexanona
BR0107592A (pt) Compostos calcilìticos
AR027349A1 (es) Derivados de amidas heterociclicas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1332149

Country of ref document: EP

REN Ceased due to non-payment of the annual fee